{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:49:50Z","timestamp":1791308990165,"version":"4.3.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1097\/01.inf.0000086955.93702.c7","type":"journal-article","created":{"date-parts":[[2003,10,2]],"date-time":"2003-10-02T04:01:58Z","timestamp":1065067318000},"page":"S158-S163","source":"Crossref","is-referenced-by-count":99,"title":["Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates"],"prefix":"10.1097","volume":"22","author":[{"given":"JAIME G.","family":"DEVILLE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STUART","family":"ADLER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PARVIN H.","family":"AZIMI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BARBARA A.","family":"JANTAUSCH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARIA RAYO","family":"MORFIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SANDRA","family":"BELTRAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BARBARA","family":"EDGE-PADBURY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHARON","family":"NABERHUIS-STEHOUWER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JON B.","family":"BRUSS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210202","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mpd.2001.119442","article-title":", and the Pediatric Prevention Network. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey.","volume":"139","author":"Sohn","year":"2001","journal-title":"J Pediatr"},{"key":"R2-3-20210202","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00006454-200001000-00012","article-title":"Occurrence of nosocomial bloodstream infections in six neonatal intensive care units","volume":"19","author":"Brodie","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"R3-3-20210202","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1542\/peds.103.4.e39","article-title":"Nosocomial infections in pediatric intensive care units in the United States","volume":"103","author":"Richards","year":"1999","journal-title":"Pediatrics"},{"key":"R4-3-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.110.4.e42","article-title":"Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists\u2019 practices","volume":"110","author":"Rubin","year":"2002","journal-title":"Pediatrics"},{"key":"R5-3-20210202","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria","volume":"42","author":"Swaney","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-3-20210202","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1381612802666220921173820","article-title":"Oxazolidinone antibacterial agents","volume":"2","author":"Brickner","year":"1996","journal-title":"Curr Pharm Des"},{"key":"R7-3-20210202","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.40.7.1745","article-title":"In vitroactivities of new oxazolidinone, antimicrobial agents against enterococci","volume":"40","author":"Eliopoulos","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-3-20210202","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitroactivities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-3-20210202","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/AAC.41.2.465","article-title":"In vitroactivities of the oxazolidinone antibiotics U-100592 and U-100766 againstStaphylococcus aureusand coagulase-negative staphylococcus species","volume":"41","author":"Jorgensen","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-3-20210202","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/j.1875-9114.1998.tb03109.x","article-title":"The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials","volume":"18","author":"Dresser","year":"1998","journal-title":"Pharmacotherapy"},{"key":"R11-3-20210202","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.42.3.721","article-title":"Comparativein vitroactivity and postantibiotic effects of oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766)versusvancomycin against Staphylococcus aureus, coagulase-negative staphylococci,Enterococcus faecalis,andEnterococcus faecium.","volume":"42","author":"Rybak","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-3-20210202","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolidversusvancomycin for the treatment of methicillin-resistantStaphylococcus aureusinfections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R13-3-20210202","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/00006454-200012000-00012","article-title":"Single dose pharmacokinetics of linezolid in infants and children","volume":"19","author":"Kearns","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"R14-3-20210202","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/00006454-200105000-00004","article-title":"Linezolid for the treatment of community-acquired pneumonia in hospitalized children","volume":"20","author":"Kaplan","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"R15-3-20210202","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.inf.0000059403.21440.2c","article-title":"Linezolidversuscefadroxil in the treatment of skin and skin structure infections in children","volume":"22","author":"Wible","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R16-3-20210202","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.inf.0000078160.29072.42","article-title":"Linezolidversusvancomycin in the treatment of Gram-positive infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R17-3-20210202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3476(96)70191-9","article-title":"Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network","volume":"129","author":"Stoll","year":"1996","journal-title":"J Pediatr"},{"key":"R18-3-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00006454-200301000-00008","article-title":"Persistent bacteremia and outcome in late onset infection among infants in a neonatal intensive care unit","volume":"22","author":"Chapman","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R19-3-20210202","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1542\/peds.107.6.1272","article-title":"Bacteremia, central catheters, and neonates: when to pull the line","volume":"107","author":"Benjamin","year":"2001","journal-title":"Pediatrics"},{"key":"R20-3-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00006454-200201000-00005","article-title":"Central venous catheter removalversusin situtreatment in neonates with coagulase-negative staphylococcal bacteremia","volume":"21","author":"Karlowicz","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R21-3-20210202","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00006454-199705000-00006","article-title":"Epidemiology of vancomycin usage at a children\u2019s hospital, 1993 through 1995","volume":"16","author":"Sinkowitz","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"R22-3-20210202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1086\/501605","article-title":"The emergence of decreased susceptibility to vancomycin inStaphylococcus epidermidis.","volume":"20","author":"Garrett","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R24-3-20210202","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJM199902183400701","article-title":", for the Glycopeptide-Intermediate Staphylococcus aureus Working Group. Emergence of vancomycin resistance in Staphylococcus aureus.","volume":"340","author":"Smith","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.inf.0000086955.93702.c7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:28:18Z","timestamp":1785767298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-200309001-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1097\/01.inf.0000086955.93702.c7","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}